Tag: regeneron-chief

French drugmaker Sanofi SA and U.S. partner Regeneron Pharmaceuticals Inc said a one-year, late-stage study of dupilumab, a monoclonal antibody designed for the treatment of skin diseases, had met its main goals. “These are the first long-term Phase 3 data that demonstrated dupilumab with topical corticosteroids was superior to topical corticosteroids alone, and provided sustained…